Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Alecta in connection with investment in Stena Renewable
Mandate

Vinge advises Alecta in connection with investment in Stena Renewable

April 01, 2021 M&A Environmental Law

Vinge has advised Alecta in connection with an investment of SEK 1.6 billion in Stena Renewable AB, of which SEK 600 million will be invested over a 5-year period.

The investment is Alecta’s first direct investment in green energy and, following completion of the transaction, Alecta will own 20 per cent of the shares in Stena Renewable. The other shareholders of the company are Stena Adactum, AMF and Norway’s largest pension company, KLP.

Stena Renewable develops, constructs and operates onshore wind farms. The company currently has 115 wind turbines located on eight wind parks in Sweden.

Vinge’s team mainly consisted of Filip Öhrner, Peter Sundgren, Manne Bergström, Carl Fredrik Wachtmeister (M&A) and Johan Cederblad (Environmental law/Real Estate).

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026